AVI BioPharma Will Present at Rodman & Renshaw Techvest 2nd Annual Security and Connectivity Investor Conference.PORTLAND, Ore. -- AVI BioPharma, Inc. (Nasdaq:AVII), today announced that Alan P. Timmins, president and COO of AVI, will present an update on the company's biodefense strategy at the Rodman & Renshaw Techvest 2nd Annual Security and Connectivity Investor Conference. The event will be held June 15 at the St. Regis Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , and Mr. Timmins is scheduled to present at 4:15 p.m. EDT. Mr. Timmins will discuss the scientific rationale behind using AVI's proprietary NEUGENE(R) antisense technology in response to bioterror threats and public health issues. He also will discuss current research supporting AVI's rapid response therapeutic approach to new and emerging threats including Ebola virus, anthrax and ricin. "AVI has developed what we believe is a truly revolutionary rapid response treatment model to respond swiftly and effectively to a variety of bioterror threats," Mr. Timmins said. "We continue to work with government agencies and academic collaborators to further these important advances in treating emerging viruses and toxins." AVI is currently testing its NEUGENE antisense drugs against several infectious and toxin-producing agents in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID USAMRIID United States Army Medical Research Institute of Infectious Diseases (US DoD) ), the Walter Reed Army Institute of Research This article is about the U.S. Army medical research institute (not the hospital). Otherwise, see Walter Reed (disambiguation). The Walter Reed Army Institute of Research (WRAIR) is the largest biomedical research facility administered by the U.S. (WRAIR), and the Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC), agency of the U.S. Public Health Service since 1973, with headquarters in Atlanta; it was established in 1946 as the Communicable Disease Center. (CDC See Control Data, century date change and Back Orifice. CDC - Control Data Corporation ). Last week, Mr. Timmins testified before the U.S. Senate Committee on Health, Education, Labor and Pensions Subcommittee on Bioterrorism and Public Health Preparedness. The panel discussion revolved around Bioshield II legislation and how the government can streamline the process of developing new technologies to effectively respond to public health threats such as bioterrorism. About AVI BioPharma AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease Polycystic Kidney Disease Definition Polycystic kidney disease (PKD) is one of the most common of all life-threatening human genetic disorders. . In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus West Nile virus, microorganism and the infection resulting from it, which typically produces no symptoms or a flulike condition. The virus is a flavivirus and is related to a number of viruses that cause encephalitis. , hepatitis C virus
"Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion